The present invention relates to a ready-to-administer parenteral dosage form of norepinephrine which comprises an aqueous solution of norepinephrine, having an anti-oxidant which is not a sulfite anti-oxidant, wherein the dosage form is stable at room temperature for prolonged period of time.

The present disclosure provides application of a compound in conformity with a general formula I, and an isomer or pharmaceutically acceptable salt thereof to preparation of a medicinal composition for treating and/or preventing a high altitude disease. The high altitude disease is selected from an acute high altitude disease or a chronic high altitude disease generated in a high altitude environment with an altitude of 2,000 m or above.

Indazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present invention concerns the use of an indazole-3-carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.

The invention relates to a silyl-containing polymer that is used, together with a tackifying resin to form an adhesive composition capable of storing and delivering drugs to the skin of a user. Typically the composition is formed into a patch which shows excellent adhesion to the skin even when drugs and other additives are dissolved into the composition.

The present disclosure encompasses compositions prepared from Boysenberry. Also encompassed are methods of preparing these compositions and methods of using these compositions, in particular, for treating or preventing disorders of the respiratory system, including amongst others: inflammation, asthma, chronic obstructive pulmonary disease, reactive airway disease, airway fibrosis, and airway remodelling.

The present disclosure encompasses compositions prepared from Boysenberry. Also encompassed are methods of preparing these compositions and methods of using these compositions, in particular, for treating or preventing disorders of the respiratory system, including amongst others: inflammation, asthma, chronic obstructive pulmonary disease, reactive airway disease, airway fibrosis, and airway remodelling.

Methods of treating diseases and conditions wherein an improvement in cardiac output, organ perfusion, or tissue oxygenation are disclosed. The methods include treatments of diseases and conditions, such as hypovolemic shock, with an a.sub.2 adrenergic agent, like centhaquin and centhaquin citrate. The method utilizes an a.sub.2 adrenergic agent administered at low doses with a low volume of resuscitation fluid. Purified centhaquin and centhaquin citrate also are disclosed.

Genotyping methods and compositions for selecting patients with cardiovascular disease who will benefit from treatment with HDL-raising or HDL mimicking agent, in particular with a CETP inhibitor/modulator

The present invention is directed to methods for determining active DPP3 in a bodily fluid sample, an assay or kit for determining active DPP3 in a bodily fluid sample, a method for diagnosing a disease or condition in a subject accompanied by or related to necrotic processes and methods of treating or preventing said disease.

Therapeutic compositions, comprising: an anti-reactive oxygen species agent and a pervious polymersome, the pervious polymersome encapsulating the anti-reactive oxygen species agent, and the pervious polymersome having therein channels defined by a channel diblock copolymer, the channels being arranged so as to retain at least some of the anti-reactive oxygen species agent within the pervious polymersome while allowing reactive oxygen species to pass into the pervious polymersome.

Method of treating a patient, comprising: administering an effective amount of a therapeutic composition, the therapeutic composition comprising an anti-reactive oxygen species agent disposed within a pervious polymersome, the pervious polymersome encapsulating the anti-reactive oxygen species agent, and the pervious polymersome having therein channels defined by a channel diblock copolymer, the channels being arranged so as to retain at least some of the anti-reactive oxygen species agent within the pervious polymersome while allowing reactive oxygen species to pass into the pervious polymersome.